Tesamorelin vs CJC-1295 — how do they actually compare?
Both are GHRH analogs but they get treated very differently in the community. Let's break it down.
Tesamorelin:
- FDA-approved (for HIV lipodystrophy)
- Strong data on reducing visceral fat
- More expensive because of pharmaceutical status
- Some vendors carry the research version
- Well-studied safety profile
CJC-1295 (with DAC):
- Longer half-life than tesamorelin
- More commonly available from research vendors
- Usually paired with a GHRP (ipamorelin, GHRP-2)
- Less clinical trial data but extensive community use
Key difference: Tesamorelin has real clinical data behind it. CJC-1295 has broader community experience but less formal research.
The practical question: If you have access to both, which makes more sense for your research goals? Tesamorelin's visceral fat data is compelling, but CJC+Ipa is the more flexible stack.
What are people running and why did you choose one over the other?
1 Reply
I wanted to share my firsthand experience comparing Tesamorelin and CJC.
While I noticed that CJC provided much better sleep than Tesamorelin, the side effects ultimately forced me to remove it from my lineup. I experienced red, itchy histamine reactions and flushing at the injection site that felt like a sting. Most concerning, however, was a recent incident where I suddenly developed hives and a severe allergic reaction, accompanied by nausea and violent vomiting.
Because I don't experience any significant side effects with Tesamorelin, I have decided to switch back to it.